| 摘要: |
| 在中华医学会皮肤性病学分会银屑病专业委员会的领导下，全国31位专家组成编写委员会在《中国银屑病诊疗指南(2018版)》的基础上，经过反复讨论和商榷，对原版指南进行补充和修订，形成了《中国银屑病诊疗指南(2023版)》。新指南对银屑病严重程度分级标准以及诊断分型标准进行了更新，并且对银屑病共病概念进行了补充完善。在辅助检查方面，新指南推荐加强无创性影像学检查的应用；在治疗方面，新指南优化了对传统药物的治疗建议，并对生物制剂及小分子靶向药物的应用指导进行了细化补充。本文就新指南的要点进行解读。 |
| 关键词: 银屑病 指南 诊断标准 治疗 |
| DOI：10.12289/j.issn.1008-0392.23286 |
| 投稿时间：2023-08-27 |
| 基金项目:国家自然科学基金（82073429,82273510）；上海市教委科研创新计划（2019-01-07-0-007-E00046）；上海市优秀学术带头人计划（20XD1403300）；上海申康中心第二轮三年行动计划重大临床研究项目（SHDC2020CR1014B） |
|
| Interpretation of guideline for the diagnosis and treatment of psoriasis in China(2023 edition) |
| SHI Yuling |
| (Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Institute of Psoriasis, School of Medicine, Tongji University, Shanghai 200443, China) |
| Abstract: |
| With the modification of 2018 edition, the Guideline for the Diagnosis and Treatment of Psoriasis in China(2023 edition) has been developed by an expert group under the Psoriasis Committee of the Chinese Society of Dermatology. The new guideline updates the criteria for severity grading and diagnostic typing of psoriasis, and improves the concept of psoriasis comorbidities. In terms of auxiliary investigation, the new guideline recommends the application of non-invasive imaging examination; in terms of treatment, the new guideline optimizes the recommendation of traditional drugs, refines and supplements the application guidance for biological agents and small-molecule targeted agents. This article interprets the main contents of the new guideline. |
| Key words: psoriasis guideline diagnostic criteria treatment |
